MRTX

Mirati Therapeutics, Inc. Common Stock
MRTX

Overview Fund Activity
Delisted

MRTX was delisted on the 22nd of January, 2024.

Back to rankings

207 hedge funds and large institutions have $2.38B invested in Mirati Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 82 increasing their positions, 67 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
207
Holders Change
-14
Holders Change %
-6.33%
% of All Funds
3.26%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
27
Increased
82
Reduced
67
Closed
41
Calls
$33.6M
Puts
$11.3M
Net Calls
+$22.3M
Net Calls Change
+$16.2M

Top Buyers

1
RI
RTW Investments
New York
$162M
2
Morgan Stanley
Morgan Stanley
New York
$103M
3
Wellington Management Group
Wellington Management Group
Massachusetts
$122M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
$29.2M
5
AG
Artal Group
Luxembourg
$74.3M

Top Sellers

1
PA
Perceptive Advisors
New York
$26M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
$0
3
KCM
Kynam Capital Management
New Jersey
$0
4
CC
Casdin Capital
New York
$860K
5
PHS
PFM Health Sciences
California
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
ACA
1
Avoro Capital Advisors
New York
$201M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$180M -$2.57M -71,100 -1%
RI
3
RTW Investments
New York
$162M +$30M +829,871 +23%
AC
4
Armistice Capital
New York
$144M +$10.3M +286,000 +8%
Wellington Management Group
5
Wellington Management Group
Massachusetts
$122M +$25M +692,273 +26%
BlackRock
6
BlackRock
New York
$120M +$2.93M +81,140 +3%
AH
7
Aviva Holdings
Bahamas
$113M – – –
Morgan Stanley
8
Morgan Stanley
New York
$103M +$28.7M +793,019 +39%
State Street
9
State Street
Massachusetts
$93.3M +$9.82M +271,919 +12%
AG
10
Artal Group
Luxembourg
$74.3M +$18.7M +517,472 +34%
BC
11
Boxer Capital
California
$72.3M – – –
CCM
12
Camber Capital Management
Massachusetts
$65M +$14.5M +400,000 +29%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$64.2M +$240K +6,638 +0.4%
PBA
14
Paradigm Biocapital Advisors
New York
$52.2M +$1.7M +46,983 +3%
BBA
15
Baker Bros. Advisors
New York
$50.9M – – –
RSCM
16
Rock Springs Capital Management
Maryland
$40.5M +$2.04M +56,386 +5%
O
17
OrbiMed
New York
$33M – – –
CS
18
Candriam SCA
Luxembourg
$31.6M +$3.96M +109,498 +14%
Assenagon Asset Management
19
Assenagon Asset Management
Luxembourg
$29.2M +$20M +552,860 +216%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$27.6M +$1.05M +29,195 +4%
OCA
21
Octagon Capital Advisors
New York
$27.1M – – –
PA
22
Perceptive Advisors
New York
$26M -$30.9M -855,031 -54%
Fiera Capital (Canada)
23
Fiera Capital (Canada)
Quebec, Canada
$25M -$633K -17,494 -2%
Franklin Resources
24
Franklin Resources
California
$23.6M +$795 +22 +0%
EAM
25
Eventide Asset Management
Massachusetts
$21.7M +$8.27M +228,898 +62%
1
2 3 4 5